EUCTR2013-000622-55-CZ进行中（未招募）不适用
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 528
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Men or women greater than or equal to 18 years of age and less than or equal to 65 years of age
- •[2] Diagnosed with primary hypercholesterolemia (HC) defined as LDL =100 mg/dL (2.6 mmol/L) and TG =450 mg/dL (5.1 mmol/L)
- •o A subset of patients (~ 20%) with an LDL-C =80 mg/dL to <100 mg/dL (=2.1 mmol/L to <2. 6 mmol/L) will also be allowed.
- •o Includes at least ~20% heterozygous familial hypercholesterolemia (HeFH) and polygenic (non-familial) HC patients.
- •[3] Are on a stable diet and stable daily dose of atorvastatin,
- •simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, or
- •pitavastatin for at least 6 weeks and further adjustments of statin dose
- •are not deemed clinically indicated by the investigator, or up to ~20% of
- •patients with history of statin intolerance (i.e. patients who cannot
- •tolerate any dose of at least 1 statin) who are not on statin treatment for
- •at least 6 weeks, with or without a stable dose of ezetimibe for at least 6
- •[4] Male patients with partner of childbearing potential: agree to use barrier protection during sexual intercourse during the study and for 3 months following the administration of the last dose of investigational product.
- •[5] Female patients including:
- •Women not of child bearing potential due to surgical sterilization
- •(hysterectomy or bilateral oophorectomy or tubal ligation) or
- •menopause. Women with an intact uterus are deemed postmenopausal if
- •they have a cessation of menses for at least 1 year (or 6 to 12 months of
- •spontaneous amenorrhea with follicle stimulating hormone >40 mIU/mL
- •(>40 IU/L); not taking hormones or oral contraceptives within 1 year.
- •Women of child bearing potential who have a negative urine or serum
- •pregnancy test, are not breast feeding, and agree to use a reliable
- •method of birth control up to at least 3 months following the last dose of
- •study drug, where reliable is defined as birth control that results in a low
- •failure rate (i.e., <1% per year) when used consistently and correctly.
- •[6] Have given informed consent to participate in the study. Women of child bearing potential who have a negative urine or serum pregnancy test and agree to use a reliable method of birth control up to at least 3 months following the last dose of study drug, where reliable is defined as birth control that results in a low failure rate (i.e., <1% per year) when used consistently and correctly.
- •[6] Have given informed consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 317
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 211
排除标准
- •[1] Have secondary HC or homozygous familial HC.
- •[2] Have had myocardial infarction (MI), unstable angina (UA), percutaneous coronary intervention, coronary artery bypass graft, stroke, or deep vein thrombosis/pulmonary embolism within 3 months of screening, or have planned cardiovascular surgery or percutaneous coronary intervention.
- •[3] Have symptoms consistent with moderate or severe heart failure or are receiving treatment for symptomatic congestive heart failure (CHF) or known left ventricular ejection fraction (LVEF) <30%. >160 mmHg or diastolic blood pressure >100 mmHg.
- •[5] Have diabetes mellitus (type 1 or 2) that requires or is likely to
- •require any injectable glucose lowering therapy (including insulins)
- •during the course of the study or have hemoglobin A1c (HbA1c) =8.5%.
- •[6] Have thyroid-stimulating hormone (TSH) levels outside normal
- •reference range for the central laboratory. Patients who are clinically euthyroid and on stable thyroid replacement therapy for at least 2months prior to screening and who are anticipated to remain on this dose throughout the trial period are acceptable exceptions to this criterion.
- •[7] Have a history of adrenal insufficiency, Cushing's syndrome, or other adrenal gland disorder.
- •[8] Have a history of vitamin E deficiency or fat malabsorption
- •[9] Have a serum creatinine =176.8 µM/L, nephrotic syndrome, or end stage renal disease and use renal replacement therapy such as
- •hemodialysis or peritoneal dialysis
- •[10] Have active hepatobiliary disease, serologic evidence of past or active hepatitis B or C, or past or active gallbladder disease.
- •[11] Have aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), or total bilirubin >2X ULN.
- •[12] Have a history or presence of a chronic muscular or neuromuscular disease including prior rhabdomyolysis or drug-induced myopathy or an unexplained/documented elevation in creatine kinase (CK) >3X ULN.
- •[13]Have hemoglobin <10 g/dL (6.2 mmol/L) in women and <11 g/dL (6.83 mmol/L) in men.
- •[14] Have a history of allergy, hypersensitivity or intolerance to drug preparations containing LY3015014, other PCSK9 antibodies, other monoclonal antibodies or any components of the formulation.
- •[15] Have a history of human immunodeficiency virus infection (HIV) infection, positive human HIV antibodies or other immune deficiency disorder.
- •[16] Have planned or are likely to require major surgery requiring
- •anesthesia or hospitalization during the course of the study.
- •[17] Have chronic alcohol or drug abuse or dependency.
- •[18] Are currently under suspicion of having any cancer or malignancy or have had a history of cancer in the past 2 years, with the exception of non-melanoma skin cancers, cervical cancer in situ, breast ductal carcinoma in situ or stage 1 prostate cancer.
- •[19] Have an active serious infection.
- •[20] Have a history or presence of cardiovascular, respiratory,
- •endocrine, gastrointestinal, hematological, autoimmune, metabolic,
- •neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data.
- •[21] Have started or stopped taking a statin or ezetimibe medication, or changed statin dose regimen within 6 weeks of randomization.
- •[22] Are on a statin regimen other than daily dosing (for example, an every-other-day statin regime
研究者
相似试验
未知
2 期
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary HypercholesterolemiaHypercholesterolemiaJPRN-jRCT2080222170Eli Lilly Japan K.K.
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolEUCTR2013-000622-55-DKEli Lilly and Company528
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolEUCTR2013-000622-55-NLEli Lilly and Company528
已完成
2 期
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemiahypercholesterolaemiahigh blood cholesterol levelsNL-OMON38601Eli Lilly80
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolPrimary hypercholesterolaemiaMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000622-55-PLEli Lilly and Company528